AJANTA PHARMA LTD. - 532331 - Participation In Investor Conference
Pls find enclosed schedule of participation in investor conference13-05-2024
13-05-2024
AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
PFA herewith written transcript of earnings call conducted on 2nd May 2024.08-05-2024
AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Public Announcement-Buyback of Shares
Submission of Public Announcement pursuant to the provisions of the SEBI (Buy-back of Securities) Regulations 201806-05-2024
AJANTA PHARMA LTD. - 532331 - Submission Of Board Resolution For Buy Back Pursuant To Regulation 30 Of SEBI (LODR) Regulations 2015.
PFA Board Resolution for Buy Back06-05-2024
AJANTA PHARMA LTD. - 532331 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
In our intimation dated 2nd May 2024, under Regulation 30 of SEBI (LODR) Regulations, 2015, we had inadvertently intimated about change of Cost Auditor. PFA correct intimation for change in cost auditors.03-05-2024
AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of SEBI (LODR), PFA Newspaper Publication of Financial Results for the quarter and year ended 31st March 2024.03-05-2024
Ajanta Pharma Q4 Results Review - Higher Opex Leads To Ebitda/Profit After Tax Miss: Motilal Oswal
Aims to consistently outperform the industry in branded generics.03-05-2024
AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 2nd May 2024 at 4.30 p.m. has been uploaded on the Company's website and can be accessed through the link: https://ajantapharma.com//images/EarningsAudio-Q4-FY2024.mp302-05-2024
Q4FY24 Quarterly & FY24 Annual Result Announced for Ajanta Pharma Ltd.
Pharmaceuticals company Ajanta Pharma announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Revenue from operations at Rs 1,054 crore against Rs 882 crore; up 20%. EBITDA at Rs 278 crore against Rs 149 crore; up 86%; EBITDA at 26%. Profit after tax at Rs 203 crore against Rs 122 crore; up 66%; PAT at 19%. FY24 Financial Highlights: Revenue from operations at Rs 4,209 crore against Rs 3,743 crore; up 12%. EBITDA at Rs 1,172 crore against Rs 783 crore; up 50%; EBITDA at 28%. Profit after tax at Rs 816 crore against Rs 588 crore; up 39%; PAT at 19%. Cashflow from operations (CFO) was Rs 785 crore, EBITDA to CFO conversion of 67%. Free cashflow (FCF) was Rs 637 crore, FCF to PAT conversion of 78%. Result PDF02-05-2024
AJANTA PHARMA LTD. - 532331 - Pursuant To Regulation 30 Of SEBI (LODR) Regulations, 2015, Pls Find Enclosed Details For: 1. Appointment Of Cost Auditors 2. Vacancy Of Cost Auditors 3. Re-Appointment Of Secretarial Auditors 4. Re-Appointment Of Tax Auditors
Pls find enclosed details towards: 1. Appointment of Cost Auditors 2. Vacancy of Cost Auditors 3. Re-appointment of Secretarial Auditors 4. Re-appointment of Tax Auditors02-05-2024